Executive Order 14293 Act of 2025
- Bill Number
- H.R. 3676
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-09-05T15:59:15Z
AI-Generated Summary
Purpose
The legislation, H.R. 3676 (titled the "Executive Order 14293 Act of 2025"), aims to convert Executive Order 14293 into statutory law. The executive order focuses on providing regulatory relief to encourage the increased production of critical medicines within the United States, addressing potential shortages and enhancing national supply chain resilience.
Key Provisions
- Codification of Executive Order: The bill declares that Executive Order 14293 (published in the Federal Register on April 2, 2025, at 90 Fed. Reg. 19615) will have the full force and effect of law, making its directives legally binding beyond the president's term.
- Short Title: The act is officially named the "Executive Order 14293 Act of 2025."
- Referral to Committees: The bill was introduced and referred to the House Committee on Energy and Commerce, and additionally to the Committee on Transportation and Infrastructure, for review of relevant provisions (e.g., those involving health regulations and supply chain logistics).
Significant Changes to Existing Law
- This bill transforms a temporary executive action into permanent federal law, ensuring the order's policies on regulatory relief—such as streamlined approvals or reduced bureaucratic hurdles for domestic drug manufacturing—cannot be easily reversed by future administrations without congressional action.
- It does not introduce new rules but embeds the executive order's existing directives (e.g., easing regulations to boost U.S.-based production of essential drugs like antibiotics or vaccines) directly into the U.S. Code, elevating them from administrative guidance to enforceable statute.
Potential Impacts
- On Government Agencies: Agencies like the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) may face mandates to prioritize domestic production, potentially accelerating permitting processes for manufacturers while requiring coordination on supply chain security. This could reduce administrative burdens but increase oversight needs.
- On Citizens: Americans could benefit from a more reliable supply of critical medicines, potentially lowering risks of shortages during emergencies (e.g., pandemics) and supporting affordable access to essential drugs produced locally.
- On International Relations: By promoting U.S. domestic production, the law may reduce reliance on foreign suppliers (e.g., from China or India for active pharmaceutical ingredients), which could strain trade ties but strengthen national security in health sectors.
Main Stakeholders Affected
- Pharmaceutical Manufacturers: Domestic companies gain regulatory incentives to expand production, while importers may face competitive pressures.
- Government Entities: FDA, HHS, and related agencies must implement and enforce the codified order, affecting their regulatory workflows.
- Healthcare Providers and Consumers: Hospitals, pharmacies, and patients stand to gain from stabilized medicine supplies, particularly for life-saving treatments.
- Foreign Suppliers: International pharmaceutical exporters could see reduced U.S. market demand, impacting global trade dynamics.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Codifying an executive order reinforces its durability against judicial challenges or executive revocation, but it must align with existing statutes like the Federal Food, Drug, and Cosmetic Act; any conflicts could lead to court reviews on regulatory authority.
- Constitutional Implications: This upholds Congress's role in legislating on interstate commerce and public health under Article I, Section 8, while limiting executive overreach by requiring legislative buy-in for ongoing policy.
- Political Implications: As a bipartisan effort (introduced by Rep. Burchett and Rep. Luna), it signals congressional support for supply chain independence, potentially influencing future debates on national security, trade policy, and healthcare funding amid ongoing concerns over global vulnerabilities exposed by events like COVID-19.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Rep. Luna, Anna Paulina [R-FL-13]
Recent Actions
- 2025-06-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-03: Introduced in House
- 2025-06-03: Introduced in House
Bill Versions
- Executive Order 14293 Act of 2025 — issued 2025-06-03 — PDF (2 pages)